Search Results - "Rahm, A K"

Refine Results
  1. 1

    Carvedilol targets human K2P3.1 (TASK1) K+ leak channels by Staudacher, K, Staudacher, I, Ficker, E, Seyler, C, Gierten, J, Kisselbach, J, Rahm, AK, Trappe, K, Schweizer, PA, Becker, R, Katus, HA, Thomas, D

    Published in British journal of pharmacology (01-07-2011)
    “…BACKGROUND AND PURPOSE Human K2P3.1 (TASK1) channels represent potential targets for pharmacological management of atrial fibrillation. K2P channels control…”
    Get full text
    Journal Article
  2. 2

    Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction by PIAZZA, G. A, RAHM, A. K, FINN, T. S, FRYER, B. H, LI, H, STOUMEN, A. L, PAMUKCU, R, AHNEN, D. J

    Published in Cancer research (Chicago, Ill.) (15-06-1997)
    “…Sulindac causes regression of and prevents recurrence of colonic adenomas in patients with familial adenomatous polyposis. Although cell cycle arrest and…”
    Get full text
    Journal Article
  3. 3

    The influence of endoscopic vein harvesting on outcomes after coronary bypass grafting: a meta-analysis of 267 525 patients by Sastry, Priya, Rivinius, Rasmus, Harvey, Rebecca, Parker, Richard A., Rahm, Ann-Kathrin, Thomas, Dierk, Nair, Sukumaran, Large, Stephen R.

    “…In recent times, practice in cardiac surgery has shifted towards using endoscopic techniques to harvest the saphenous vein from the leg for use as a bypass…”
    Get full text
    Journal Article
  4. 4

    Die Lebensqualität von Patienten mit implantierbarem Kardioverter-Defibrillator aus salutogenetischer Sicht: Eine qualitative Studie der kardiologischen Versorgungsforschung by Senn, K., Zitron, E., Katus, H. A., Thomas, D., Ullrich, C., Rahm, A.-K.

    “…Zusammenfassung Hintergrund Die Lebensqualität von Patienten mit implantierbarem Kardioverter-Defibrillator (ICD) wird von therapiebedingten Faktoren…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7
  8. 8

    Quality of life in patients with implantable cardioverter-defibrillator from a salutogenic perspective : A qualitative study in cardiologic health service research by Senn, K, Zitron, E, Katus, H A, Thomas, D, Ullrich, C, Rahm, A-K

    “…Evidence on disease-related quality of life (DRQoL) of patients with implantable cardioverter-defibrillators (ICDs) has been described heterogeneously…”
    Get full text
    Journal Article
  9. 9

    Impact of BRCA1 testing on women with cancer: a pilot study by Wood, M E, Mullineaux, L, Rahm, A K, Fairclough, D, Wenzel, L

    Published in Genetic testing (2000)
    “…We sought to understand better the impact of genetic testing and counseling in a group of women who had early breast cancer (age <50) or ovarian cancer and a…”
    Get more information
    Journal Article
  10. 10

    PS1-09: Public Opinion of Family History and Genetic Testing for Common Diseases: Results from Focus Groups with Kaiser Permanente Colorado Members by Rahm, A. K.

    Published in Clinical medicine & research (01-12-2010)
    “…BACKGROUND: and Aims: With the advent of personalized medicine, consumers are routinely exposed to information about new gene discoveries, family history, and…”
    Get full text
    Journal Article
  11. 11
  12. 12

    C-B3-04: Media Analysis of Genetic Testing Information for Common Disease Presented to the Public by Rahm, A. K.

    Published in Clinical medicine & research (01-03-2010)
    “…Background/Aims: With the advent of personalized medicine, consumers are routinely exposed to information and direct- to- consumer (DTC) advertising of various…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15

    Carvedilol targets human K 2P 3.1 (TASK1) K + leak channels by Staudacher, K, Staudacher, I, Ficker, E, Seyler, C, Gierten, J, Kisselbach, J, Rahm, AK, Trappe, K, Schweizer, PA, Becker, R, Katus, HA, Thomas, D

    Published in British journal of pharmacology (01-07-2011)
    “…BACKGROUND AND PURPOSE Human K 2P 3.1 (TASK1) channels represent potential targets for pharmacological management of atrial fibrillation. K 2P channels control…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20